ArticleFrontiers in cell and developmental biology2026
Induced pluripotent stem cells from sporadic pulmonary veno-occlusive disease exhibit altered endothelial commitment and stress-related transcriptional programs.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hypertension characterized by progressive vascular remodeling, with limited understanding of its cellular and molecular mechanisms, particularly in sporadic cases lacking identifiable genetic mutations. We investigated whether patient-derived induced pluripotent stem cells (iPSCs) recapitulate disease-associated cellular phenotypes and transcriptional alterations in sporadic PVOD. Methods: Integration-free iPSCs were generated from a patient with sporadic PVOD and differentiated toward endothelial and hematopoietic lineages. Endothelial differentiation capacity was assessed by flow cytometry, and transcriptomic profiling was performed using RNA sequencing followed by differential gene expression and gene set enrichment analyses. Results: PVOD-derived iPSCs demonstrated preserved hemangioblast generation but reduced endothelial commitment compared with control cells. Transcriptomic profiling revealed clear segregation between PVOD-derived and control samples by principal component analysis, indicating distinct global gene expression patterns. Differential expression analysis identified genes associated with cellular stress and metabolic regulation, while gene set enrichment analysis demonstrated enrichment of reactive oxygen species and transforming growth factor-β (TGF-β) signaling pathways, consistent with altered stress-related transcriptional programs. Discussion: These findings indicate that iPSCs derived from a patient with sporadic PVOD exhibit altered endothelial differentiation and distinct stress-related transcriptional signatures. This patient-specific iPSC model provides a platform for investigating disease-associated cellular alterations in sporadic PVOD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.